An Open Label, Dose Escalation Followed by Dose Expansion, Safety and Tolerability Trial of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Subjects With Solid Malignant Tumors
Phase of Trial: Phase I/II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs CAN 04 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
- Focus Adverse reactions
- Acronyms CANFOUR
- Sponsors Cantargia
- 13 Oct 2017 According to a Cantargia media release, the first patient in this trial has received three cycles of treatment with CAN04. The first patient has formally completed the safety evaluation period according to the clinical protocol. The results from the first part of this trial are expected during summer 2018.
- 31 Aug 2017 Status changed from not yet recruiting to recruiting.
- 21 Jul 2017 According to a Cantargia media release, clinical trial application for this trial has been approved by the regulatory authorities as well as the ethics committees in Denmark and Norway. The review is ongoing in additional countries.